Autophagy

Autophagy is an intracellular catabolic mechanism. In certain stressful situations, lysosomes degrade degenerated, damaged, aged or non-functional cells, organelles and biomolecules such as proteins and nucleic acids to achieve cellular protection and organelles from cell damage. Autophagy is achieved by forming a bilayer membrane structure in the cytoplasm that wraps the material to be removed and transports it to the lysosome for degradation. In multicellular organisms, newly formed autophagic vesicles form autophagic endosomes by fusing with vesicles in different stages of the endocytic lysosomal pathway, such as early endosomes and late endosomes, before fusing with lysosomes, a process known as autophagic vesicle maturation. Abnormalities in autophagosome maturation, which is precisely regulated by cellular trophic state and stress signaling pathways, lead to the accumulation of large amounts of damaged organelles and toxic protein aggregates in cells.

Cat. No.	Product name
BP12358	Ganoderiol F
BP12358	Ganoderiol F has anti-inflammatory, cytotoxic and anti-HIV activity, it inhibits activity of topoisomerases in vitro, and it inhibits human immunodeficiency virus-1 protease with IC(50) values of 20-40 microM. It induced HO-1 expression, activation of the mitogen-activated protein kinase EKR and up-regulation of cyclin-dependent kinase inhibitor p16 and suppressed lipopolysaccharide (LPS)-induced nitric oxide (NO) production.
BP12359	Tezacaftor
BP12359	VX-661 is a small molecule that can be used as a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) gene function.
BP12360	Oxyphenisatin acetate
BP12360	Oxyphenisatin acetate inhibits the growth of the breast cancer cell lines MCF7, T47D, HS578T, and MDA-MB-468.
BP12361	Succinylsulfathiazole
BP12361	Succinylsulfathiazole is a sulfonamide. An ultra long-acting drug.
BP12362	Danthron
BP12362	Danthron is a natural product, regulates glucose, and lipid metabolism by activating AMPK.
BP12363	U0126-EtOH
BP12363	U0126-EtOH is a non-ATP competitive specific inhibitor of MEK1/2 (IC50: 0.07/0.06 μM).
BP12364	AZD 6482
BP12364	AZD 6482 is a potent and selective p110β inhibitor with IC50 of 0.69 nM and a PI3Kβ inhibitor with IC50 of 10 nM.
BP12365	Azithromycin hydrate
BP12365	Azithromycin dihydrate is a semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.
BP12366	Dexamethasone acetate
BP12366	Dexamethasone Acetate is the acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones.
BP12367	Trifluoperazine
BP12367	Trifluoperazine is a Dopamine D2 receptor inhibitor(IC50 : 1.2 nM), and Treatment of schizophrenia.
BP12368	Zoledronic Acid
BP12368	Zoledronate is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
BP12369	Bicyclol
BP12369	Bicyclol(SY 801) is an anti-hepatitis drug. Oral administration of bicyclol normalizes the elevated serum transaminases (ALT, AST) by 50% in chronic viral hepatitis B and C, and also has a certain level of inhibiting HBV and HCV replication. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may reduce YMDD mutant and side effects and increase the anti-viral efficacy.
BP12370	Tazarotene
BP12370	Tazarotene is a synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation.
BP12371	Syringin
BP12371	Syringin is a compound with antitumor, antiproliferative, immunomodulatory and platelet aggregation inhibiting effects.
BP12372	Hydroxychloroquine
BP12372	Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
BP12373	MRT67307
BP12373	Through its effects on ULK1 and ULK2, MRT67307 blocks autophagy. MRT67307 prevents the phosphorylation of IRF3 and the production of IFN-β and increases toll-like receptor-induced IL-10 and IL-1ra secretion in macrophages. MRT67307 is a kinase inhibitor that has been shown to inhibit TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), the salt-inducible kinases (SIKs; IC50s =250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively).
BP12374	IOWH-032
BP12374	IOWH032, a synthetic CFTR inhibitor, has been investigated for the treatment of cholera, diarrhea, and secretory diarrhea.
BP12375	Burixafor hydrobromide
BP12375	Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.
BP12376	CZC-25146
BP12376	CZC-25146 is an effective, specific and metabolically stable LRRK2 inhibitor with IC50 of 4.76/6.87 nM for wild-type LRRK2(Leucine-rich repeat kinase-2) and G2019S LRRK2, respectively.
BP12377	CZC-54252
BP12377	CZC-54252 is a potent inhibitor of LRRK2.